These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26717800)

  • 21. Canakinumab in gout.
    Schlesinger N
    Expert Opin Biol Ther; 2012 Sep; 12(9):1265-75. PubMed ID: 22784099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.
    Schlesinger N; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; So A
    Arthritis Res Ther; 2011 Mar; 13(2):R53. PubMed ID: 21439048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis.
    Jena M; Tripathy A; Mishra A; Maiti R
    Inflammopharmacology; 2021 Feb; 29(1):35-47. PubMed ID: 32918702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on the pathology and clinical management of gouty arthritis.
    Gonzalez EB
    Clin Rheumatol; 2012 Jan; 31(1):13-21. PubMed ID: 22069122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canakinumab for gout: a specific, patient-profiled indication.
    Perez-Ruiz F; Chinchilla SP; Herrero-Beites AM
    Expert Rev Clin Immunol; 2014 Mar; 10(3):339-47. PubMed ID: 24451032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and Treatment of Gout and Pseudogout for Everyday Practice.
    Sidari A; Hill E
    Prim Care; 2018 Jun; 45(2):213-236. PubMed ID: 29759121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
    Terkeltaub R; Sundy JS; Schumacher HR; Murphy F; Bookbinder S; Biedermann S; Wu R; Mellis S; Radin A
    Ann Rheum Dis; 2009 Oct; 68(10):1613-7. PubMed ID: 19635719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.
    Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV
    Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of acute and chronic gouty arthritis: present state-of-the-art.
    Schlesinger N
    Drugs; 2004; 64(21):2399-416. PubMed ID: 15481999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-inflammatory effects of traditional mixed extract of medicinal herbs (MEMH) on monosodium urate crystal-induced gouty arthritis.
    Nam JS; Jagga S; Sharma AR; Lee JH; Park JB; Jung JS; Lee SS
    Chin J Nat Med; 2017 Aug; 15(8):561-575. PubMed ID: 28939019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
    Curiel RV; Guzman NJ
    Semin Arthritis Rheum; 2012 Oct; 42(2):166-78. PubMed ID: 22560299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Canakinumab: a promising treatment in rheumatology].
    Fabreguet I; So A
    Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hyperuricemia and gout : New aspects of an old disease].
    Witt M; Schulze-Koops H
    Internist (Berl); 2016 Jul; 57(7):656-65. PubMed ID: 27286837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-Energy CT in Patients with Suspected Gouty Arthritis: Effects on Treatment Regimen and Clinical Outcome.
    Metzger SC; Koehm M; Wichmann JL; Buettner S; Scholtz JE; Beeres M; Kerl JM; Albrecht MH; Hammerstingl R; Vogl TJ; Bauer RW
    Acad Radiol; 2016 Mar; 23(3):267-72. PubMed ID: 26749327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slowly melting the urate snow in joints: Explaining gout attacks to patients.
    Shimizu T; Rooks MJ
    Int J Rheum Dis; 2021 Mar; 24(3):297-299. PubMed ID: 33523569
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of gouty arthritis in patients with chronic kidney disease.
    Abdellatif AA; Elkhalili N
    Am J Ther; 2014; 21(6):523-34. PubMed ID: 22960848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-interleukin-1 therapy in the management of gout.
    Schlesinger N
    Curr Rheumatol Rep; 2014 Feb; 16(2):398. PubMed ID: 24407823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Causes, mechanisms and possible therapeutic targets of gout].
    Manigold T
    Ther Umsch; 2016; 73(3):147-52. PubMed ID: 27008447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Severe tophaceous gouty arthritis can be treated but is still overlooked in healthcare].
    Hamad AJA; Rasmussen C
    Ugeskr Laeger; 2022 Feb; 184(7):. PubMed ID: 35179111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updates in the management of gout.
    Keith MP; Gilliland WR
    Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.